ArticleAdvances in hematology2012
Molecular action of lenalidomide in lymphocytes and hematologic malignancies.
Article in Advances in hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.The Lancet. Oncology · 2014Trial
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.Molecular oncology · 2014Trial
- Long-Term Response to Single-Agent Lenalidomide in an Elderly Patient with Relapsed Hepatosplenic T-Cell LymphomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation.OncoTargets and therapy · 2026Review
- Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China.Annals of hematology · 2025Article
- Identification and prognostic analysis of propionate metabolism-related genes in head and neck squamous cell carcinoma.Frontiers in oncology · 2025Article
- Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.EClinicalMedicine · 2024Article
- A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.Bone marrow transplantation · 2024Article
- Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.Cancers · 2023Review
- Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review.The Journal of international medical research · 2022Review
- The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells.Frontiers in immunology · 2022Review
- Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.Frontiers in immunology · 2022Review
- Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2022Review
- Review
- Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.Journal for immunotherapy of cancer · 2021Article
- Targeted Treatment of Follicular Lymphoma.Journal of personalized medicine · 2021Review
- "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.Frontiers in immunology · 2020Review
- Low absolute NK cell counts in peripheral blood are associated with inferior survival in patients with mantle cell lymphoma.Cancer biomarkers : section A of Disease markers · 2019Article
- Impact of lenalidomide exposure on blood cell collection for autotransplants in persons with POEMS syndrome.Archives of medical science : AMS · 2018Article
- Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.Bone marrow transplantation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The immunomodulatory agent, lenalidomide, is a structural analogue of thalidomide approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). This agent is also currently under active investigation for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), as well as in drug combinations for some solid tumors and mantle cell lymphoma (MCL). Although treatment with lenalidomide has translated into a significant extension in overall survival in MM and MDS and has superior safety and efficacy relative to thalidomide, the mechanism of action as it relates to immune modulation remains elusive. Based on preclinical models and clinical trials, lenalidomide, as well as other structural thalidomide derivatives, enhances the proliferative and functional capacity of T-lymphocytes and amplifies costimulatory signaling pathways that activate effector responses and suppress inflammation. This paper summarizes our current understanding of T- and natural killer (NK) cell pathways that are modified by lenalidomide in hematopoietic neoplasms to inform future decisions about potential combination therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.